|
GTF2IRD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62470037423645E-12 |
| Normal-vs-Stage2 |
1.990010E-04 |
| Normal-vs-Stage3 |
2.2726265314077E-12 |
| Normal-vs-Stage4 |
1.60530477799625E-11 |
| Stage1-vs-Stage2 |
3.415000E-01 |
| Stage1-vs-Stage3 |
8.565600E-01 |
| Stage1-vs-Stage4 |
3.320000E-01 |
| Stage2-vs-Stage3 |
2.965200E-01 |
| Stage2-vs-Stage4 |
1.510610E-01 |
| Stage3-vs-Stage4 |
4.941600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
2.08049999999016E-05 |
| Normal-vs-Asian |
5.7237999995241E-07 |
| Caucasian-vs-AfricanAmerican |
9.732000E-01 |
| Caucasian-vs-Asian |
5.543800E-01 |
| AfricanAmerican-vs-Asian |
7.028200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.02071692712025E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
7.085600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62592161956354E-12 |
| Normal-vs-Age(41-60Yrs) |
3.44169137633799E-15 |
| Normal-vs-Age(61-80Yrs) |
5.4626999590468E-09 |
| Normal-vs-Age(81-100Yrs) |
1.12330000001659E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.723200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.709900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.130400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.583400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.022800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.385600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.248400E-01 |
| Classical-VS-Follicular |
1.04420028179675E-10 |
| Classical-VS-Other |
8.663200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.51370000001094E-06 |
| Tall-VS-Other |
5.790400E-01 |
| Tall-VS-Normal |
2.44590014908397E-10 |
| Follicular-VS-Other |
3.997700E-02 |
| Follicular-VS-Normal |
2.173800E-02 |
| Other-VS-Normal |
2.081800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22170060126814E-11 |
| Normal-vs-N1 |
8.11199996064715E-09 |
| N0-vs-N1 |
1.335420E-01 |
|
|
